AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19559191
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg) plus aspirin (100 mg) daily
Trial: 15226784
Drug: L-arginine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (9 g/day for 7 days)
Trial: 8277768
Drug: Cimetidine alone
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine alone (800 mg twice a day)
Trial: 8277768
Drug: Cimetidine with
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine with DMSO (500 mg, four times a day)
Trial: 8277768
Drug: Cimetidine with
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine with allopurinol (50 mg, four times a day)
Trial: 8277768
Drug: Cimetidine alone
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine alone (800 mg at bedtime)
Trial: 8277768
Drug: Cimetidine with
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine with DMSO (500 mg at bedtime)
Trial: 8277768
Drug: Cimetidine with
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine with allopurinol (50 mg at bedtime)
Trial: 2973595
Drug: Cefotaxime-Amikacin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime-Amikacin combination
Trial: 30016417
Drug: Active-suspension seat
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-suspension seat
Trial: 30016393
Drug: Industry-standard air-suspension
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Industry-standard air-suspension seat
Trial: 28851779
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVA) with sham photodynamic therapy (sPDT)
Trial: 18458204
Drug: Induction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of catecholamine depletion (CD) by oral administration of alpha‐methylparatyrosine
Trial: 18458204
Drug: Sham depletion
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham depletion using identical capsules containing hydrous lactose
Trial: 15071276
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists)
Trial: 15071269
Drug: Prophylactic ICD
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic ICD therapy
Trial: 8799518
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 50 micrograms kg‐1 of diamorphine
Trial: 8799518
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 200 micrograms kg‐1 of diamorphine
Trial: 8799518
Drug: M3G: morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M3G: morphine steady-state plasma concentration ratio
Trial: 8799518
Drug: M6G: morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M6G: morphine steady-state plasma concentration ratio
Trial: 2846132
Drug: Propranolol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (both doses)
Trial: 30770034
Drug: Calmer treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calmer treatment, n = 5
Trial: 26615376
Drug: 15 mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/Kg intravenous valproate
Trial: 22495786
Drug: Oral alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alcohol (1 g/kg) administration before ART
Trial: 22495786
Drug: Post-ART alcohol
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-ART alcohol administration
Trial: 18091486
Drug: McKenzie treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McKenzie treatment
Trial: 26188020
Drug: Oral antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidant cocktail (AOC)
Trial: 23107171
Drug: Multiphasic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphasic injection protocol (protocol II) with 89 mL Ioversol
Trial: 23107171
Drug: Standard uniphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard uniphasic injection protocol (protocol I) with 100 mL Ioversol
Trial: 23107171
Drug: Multiphasic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphasic injection protocol (protocol II)
Trial: 23107171
Drug: Standard uniphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard uniphasic injection protocol (protocol I)
Trial: 23107171
Drug: Multiphasic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphasic injection technique
Trial: 21969502
Drug: Gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine alone (1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks)
Trial: 21969502
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus radiotherapy (600 mg/m(2)/wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m(2) for 3 of 4 weeks plus radiotherapy starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy)
Trial: 18335584
Drug: Inflamed tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflamed tooth and implant sites
Trial: 7821319
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone (single loading dose of 25.7 +/- 0.9 mg.kg-1 body weight)
Trial: 7821319
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (bolus infusion of 3-5 mg.kg-1 over 30 min, followed by continuous infusion of 10-15 mg.kg-1 for 24 h)
Trial: 3209830
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic therapy (penicillin-gentamicin-metronidazole)
Trial: 30225762
Drug: Religious psychotherapy
RxNorm normalized name: red delicious apple allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Religious psychotherapy emphasizing the importance of prayers (reading prayers 15 and 23 of the SahifehSajjadiyeh book at the beginning of treatment sessions)
Trial: 26421385
Drug: MTX and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX and ω‐3 fatty acids (1000 mg/d)
Trial: 22805060
Drug: Dopamine (amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (amphetamine administration)
Trial: 20818716
Drug: Plasma filtration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma filtration (twice weekly in Weeks 1, 2, 4, 7, and 10)
Trial: 11437398
Drug: Chlorambucil (CB):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2‐week interval, with 3 subsequent 2‐week treatment periods at the same dose, separated by 2‐week intervals
Trial: 11437398
Drug: Chlorambucil (CB)
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil (CB) given concurrently with interferon (IFN) at a dose of 3 x 10(6) units thrice weekly, subcutaneously, throughout the 18‐week treatment period
Trial: 11437398
Drug: Maintenance IFN
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance IFN at the same dose and schedule as initial treatment
Trial: 9488619
Drug: Clodronate 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1600 mg daily
Trial: 27569526
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning tool predicting treatment outcomes based on patient-reportable information
Trial: 12805393
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 64 mg daily
Trial: 12805393
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 96 mg daily
Trial: 12805393
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 192 mg daily
Trial: 12805393
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 384 mg daily
Trial: 10485241
Drug: Flow rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flow rate of 2.0 ml/s
Trial: 10485241
Drug: Flow rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flow rate of 3.0 ml/s
Trial: 10485241
Drug: Flow rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow rates of 2.0 ml/s, 3.0 ml/s, and 4.0 ml/s
Trial: 10485241
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 120 ml contrast medium with a flow rate of 3.0 ml/s
Trial: 8561334
Drug: Etidocaine 1%
RxNorm normalized name: etidocaine 1% preservative-free injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidocaine 1% (10 mL)
Trial: 28592147
Drug: Mixed strategy
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed strategy combining the same outpatient program associated with a weekly multidisciplinary intervention
Trial: 22804972
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium phosphate (50 mg/kg of fat-free mass per day)
Trial: 15067698
Drug: Unmanipulated drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmanipulated drug
Trial: 11144994
Drug: Scopolamine 0.5
RxNorm normalized name: scopolamine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.5 mg as an intravenous (i.v.) infusion over 15 minutes
Trial: 11144994
Drug: Scopolamine 0.5
RxNorm normalized name: scopolamine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.5 mg as an intramuscular (i.m.) injection
Trial: 6448620
Drug: Atropine (large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (large doses)
Trial: 6448620
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (conventional doses)
Trial: 29458401
Drug: Ding-Kun-Dan (DKD)
RxNorm normalized name: Ding xiang
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ding-Kun-Dan (DKD) pre-treatment for 3 months before IVF/ICSI
Trial: 17550787
Drug: quetiapine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine monotherapy (n=19)
Trial: 17550787
Drug: quetiapine add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine add-on therapy (n=22)
Trial: 15931573
Drug: Pterocarpus marsupium
RxNorm normalized name: Pterocarpus marsupium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pterocarpus marsupium extract (PM extract) 450 mg
Trial: 12929273
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg via a 15-minute infusion)
Trial: 12929273
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg via a two-hour infusion)
Trial: 8842930
Drug: Geriatrics-focused acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatrics-focused acute medicine inpatient rotation with a geriatrics-trained internist attending (n = 44)
Trial: 8842930
Drug: Geriatrics-focused acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatrics-focused acute medicine inpatient rotation with a non-geriatrics-trained internist attending (n = 25)
Trial: 1530836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 40 micrograms ipratropium and 100 micrograms fenoterol
Trial: 6238551
Drug: Metoclopramide, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide, 10 mg
Trial: 6238551
Drug: Cimetidine, 300
RxNorm normalized name: Cimetidine, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 300 mg
Trial: 6238551
Drug: Metoclopramide, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide, 10 mg and Cimetidine, 300 mg
Trial: 3946851
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline (10 +/- 1 mg/kg, orally)
Trial: 26829597
Drug: Lamotrigine augmentation
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine augmentation therapy at 100 mg/d for subjects not taking valproate and 75 mg/d for subjects taking valproate.
Trial: 26829597
Drug: Lamotrigine augmentation
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine augmentation therapy (specific doses based on valproate use).
Trial: 18564199
Drug: Serotonin-noradrenalin reuptake
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin-noradrenalin reuptake inhibitor (SNRI)
Trial: 1604872
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) administered as a single daily dose
Trial: 1604872
Drug: Divided doses
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided doses of valproic acid (VPA) thrice daily
Trial: 2857803
Drug: Dipyridamole 75
RxNorm normalized name: dipyridamole 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 75 mg and Aspirin 330 mg
Trial: 30482552
Drug: Clonidine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 3 μg.kg−1 with bupivacaine 0.165%
Trial: 30482552
Drug: Clonidine 1
RxNorm normalized name: apraclonidine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 1 μg.kg−1 with bupivacaine 0.165%
Trial: 30482552
Drug: Clonidine 2
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 2 μg.kg−1 with bupivacaine 0.165%
Trial: 30342902
Drug: Placebo bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bleaching (ACP gel) followed by resin infiltration
Trial: 27050244
Drug: 70 ml
RxNorm normalized name: ALCOHOL 70 mL TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 ml of 'BEET It Sport' nitrate shot containing 6.4 millimoles (mmol.L) or 400 mg of nitrate
Trial: 24840756
Drug: Caffeine therapy
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine therapy
Trial: 17521311
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg daily for 2 weeks
Trial: 16390760
Drug: HT +
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT + FA (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily and 5 mg folic acid/day)
Trial: 16390760
Drug: HT +
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT + placebo (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily)
Trial: 12015519
Drug: Parenteral 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral 17beta‐estradiol (7.5 microg/24 h) delivered by a vaginal ring (Estring) for 12 months
Trial: 12015519
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 12 months
Trial: 10725861
Drug: Immunostains for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunostains for prostate-specific antigen, MUC-2, androgen receptor, and Ki-67
Trial: 1623678
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg/day for one month)
Trial: 6202678
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg subcutaneous disulfiram implant
Trial: 6202678
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg subcutaneous disulfiram implant
Trial: 6202678
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg subcutaneous disulfiram implant
Trial: 26990867
Drug: Topical oestriol
RxNorm normalized name: Oestriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oestriol cream for 6 weeks
Trial: 10901475
Drug: Pilocarpine 2%
RxNorm normalized name: PILOCARPINE 2% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 2% three times daily
Trial: 9488944
Drug: THP (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THP (20 mg dissolved in 40 ml saline or 5% dextrose, administered intravesically once a week for 10 weeks)
Trial: 9488944
Drug: Control (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (40 ml saline administered intravesically once a week for 10 weeks)
Trial: 8405521
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen/10 mg progestin
Trial: 8290177
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg conjugated equine estrogen
Trial: 30349198
Drug: GLA5PR GLARS-NF1
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLA5PR GLARS-NF1 150 mg
Trial: 30349198
Drug: GLA5PR GLARS-NF1
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLA5PR GLARS-NF1 300 mg
Trial: 30349198
Drug: GLA5PR GLARS-NF1
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLA5PR GLARS-NF1 450 mg
Trial: 30349198
Drug: GLA5PR GLARS-NF1
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLA5PR GLARS-NF1 600 mg
Trial: 30349198
Drug: GLA5PR GLARS-NF1
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLA5PR GLARS-NF1 150-450 mg
Trial: 30349198
Drug: GLA5PR GLARS-NF1
RxNorm normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLA5PR GLARS-NF1 150-600 mg
Trial: 24008819
Drug: 2-1 intramuscular
RxNorm normalized name: Hutbti3_2_1
DrugBank: Romilkimab (DB16318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-1 intramuscular (IM) regimen (group A)
Trial: 23872591
Drug: Statins plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins plus niacin (1500 mg daily)
Trial: 21178911
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg hyperbaric bupivacaine plus 25 µg fentanyl
Trial: 21178911
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg hyperbaric levobupivacaine plus 25 µg fentanyl
Trial: 17143000
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid treatment (SST)
Trial: 17143000
Drug: Nonsteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroid treatment (NST)
Trial: 10969306
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5% (n = 10)
Trial: 10969306
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5%
Trial: 7871905
Drug: Blocking 5-HT3
RxNorm normalized name: bentoquatam
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blocking 5-HT3 receptors with ondansetron or tropisetron-hydrochloride
Trial: 3340422
Drug: 1.1 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 micrograms/kg fentanyl (open and double-blind intravenous infusion)
Trial: 29603299
Drug: One-visit root
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit root canal treatment with 2% chlorhexidine (CHX) final rinse
Trial: 29603299
Drug: Two-visit root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit root canal treatment with calcium hydroxide (CH) dressing
Trial: 28302101
Drug: Culturally-grounded lifestyle
RxNorm normalized name: Turmeric,ground
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally-grounded lifestyle intervention (weekly nutrition and wellness sessions, physical activity sessions twice a week for 6 months, followed by 3 months of booster sessions)